Pfizer › Pfizer (NYSE: PFE) has been a terrible investment over the past three years. Revenue and earnings have generally moved in the wrong direction, as the company has been unable to follow up on ...

Most important is anti-blood-clot medicine Eliquis, which is due to lose patent exclusivity in 2026. Eliquis emerged last year as Pfizer’s top-performing drug, having grown rapidly to bring in $7.4bn ...

Pfizer delivered a strong Q2 earnings beat, raising FY2025 guidance and demonstrating effective cost-cutting. Learn why PFE ...

The tariff threat come just a few days after the White House sent letters to major drugmakers demanding slashed prices for US ...

Pfizer Inc (NYSE:PFE) is one of the Top 10 Stocks Wall Street is Buzzing About These Days. Josh Brown, CEO of Ritholtz Wealth Management, explained in a recent program on CNBC why he’s bearish on ...